electroCore (ECOR) Corporate presentation summary

Product portfolio

• gammaCore is an FDA-cleared, non-invasive vagus nerve stimulator for prevention and treatment of primary headache in adults and adolescents; it can be used alone or alongside existing treatments.

• Quell is FDA-authorized for fibromyalgia symptoms; revenue reached $4.0M through June 30, 2026, growing ~30% sequentially to $1.3M in Q2 2026.

• Truvaga wellness products target stress, sleep, calm and clarity; TAC-STIM targets human performance, including attention, fatigue and mood.

• The portfolio spans prescription, general wellness and human-performance products, with multiple price points and business models for end users.

Commercial opportunity

• Commercial priorities include VA prescription sales, Department of Defense opportunities, clinic-based adoption, eCommerce wellness sales and international expansion.

• Estimated TAM: VA $2.9B, U.S. commercial $101M, health and wellness $33B, and international $9.7B.

• Management cited $20B in annual out-of-pocket spending on chronic pain treatments, over 39M U.S. adults affected by primary headache, and fibromyalgia in 6% of U.S. adults.

• Commercial expansion includes 17 newly recruited, contracted and trained 1099 representatives across new regional territories, with incentives redesigned to support cost efficiency.

Financial performance and outlook

• H1 2026 revenue was $19M, up 35% YoY; net loss improved 17% and Adjusted EBITDA net loss improved 26% from the prior-year period.

• Total cash was $10.0M at June 30, 2026; gross margins were cited at ~85%.

• FY 2026 revenue guidance was raised to growth above 30% over FY 2025; positive Adjusted EBITDA is targeted in Q3 2027.

• Sales and marketing expense as a percentage of revenue is expected to decline over time.